Sotagliflozin Tablets 400 mg are an oral dual inhibitor of SGLT1 and SGLT2.
It inhibits glucose absorption in the intestine (SGLT1) and glucose reabsorption in the kidney (SGLT2), thereby lowering blood glucose through insulin‑independent pathways.
It also provides significant cardiorenal protection, particularly in patients with heart failure and chronic kidney disease.
Composition
Each film‑coated tablet contains:
Sotagliflozin …… 400 mg
Indications
Treatment of type 2 diabetes mellitus in adults to improve glycemic control.
Reduction of cardiovascular death and hospitalization for heart failure in adults with heart failure (HFrEF or HFpEF).
Renal protection in patients with chronic kidney disease associated with type 2 diabetes.
Key Features
Dual inhibition of SGLT1 and SGLT2
Improves both fasting and postprandial blood glucose
Proven cardiovascular and renal protective effects
Once‑daily oral administration
Low risk of hypoglycemia when used alone
Good safety and tolerability profile
Manufactured under strict GMP conditions
Complies with international pharmacopoeial standards
Complete registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Prescription-only medicine.
Contraindicated in patients with hypersensitivity to sotagliflozin.
Monitor for hypotension, ketoacidosis, and genital mycotic infections.
Use with caution in renal impairment; adjust dose or discontinue as needed.
To be used under medical supervision.
